Expertise in
16
conditions

Dr. Keisuke Shirai

Dartmouth-Hitchcock Health
Dartmouth-Hitchcock Clinic
Lebanon, NH
Expertise in
16
conditions
Specialties:Hematology Oncology | Palliative Medicine | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Keisuke Shirai is a Hematologist Oncology specialist and a Palliative Medicine provider in Lebanon, New Hampshire. Dr. Shirai is highly rated in 16 conditions, according to our data. His top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Lung Adenocarcinoma. Dr. Shirai is currently accepting new patients.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Palliative Medicine
Oncology
Licenses
Hospice and Palliative Medicine in NH
Hospital Affiliations
Mary Hitchcock Memorial Hospital
North Country Hospital And Health Center
New London Hospital
Cheshire Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem

Locations

DARTMOUTH-HITCHCOCK CLINIC
1 Medical Ctr Dr, Lebanon, NH 03756
603-650-5000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: PV-10, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Enrollment Status: Terminated
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

69 Total Publications

Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy.
Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy.
Journal: Journal for immunotherapy of cancer
Published: October 15, 2024
Similar Doctors
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Lansigan is a Hematologist Oncology specialist and a Hematologist in Lebanon, New Hampshire. Dr. Lansigan is highly rated in 38 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), T-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Lansigan is currently accepting new patients.

Expertise in
13
conditions
Dr. Konstantin H. Dragnev
Hematology Oncology | Oncology
Expertise in
13
conditions
Dr. Konstantin H. Dragnev
Hematology Oncology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Konstantin Dragnev is a Hematologist Oncology specialist and an Oncologist in Lebanon, New Hampshire. Dr. Dragnev is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Dragnev is currently accepting new patients.

Expertise in
14
conditions
Dr. Kathryn C. Hourdequin
Hematology Oncology | Oncology | Hematology
Expertise in
14
conditions
Dr. Kathryn C. Hourdequin
Hematology Oncology | Oncology | Hematology

Mary Hitchcock Memorial Hospital

1 Medical Ctr Dr, 
Lebanon, NH 
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Hourdequin is a Hematologist Oncology specialist and an Oncologist in Lebanon, New Hampshire. Dr. Hourdequin is highly rated in 14 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Colorectal Cancer. Dr. Hourdequin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile